Antibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- HPA027376 - Provider product page
- Provider
- Atlas Antibodies
- Proper citation
- Atlas Antibodies Cat#HPA027376, RRID:AB_1855139
- Product name
- Anti-PDK1
- Antibody type
- Polyclonal
- Description
- Polyclonal Antibody against Human PDK1, Gene description: pyruvate dehydrogenase kinase, isozyme 1, Validated applications: IHC, Uniprot ID: Q15118, Storage: Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Reactivity
- Human
- Host
- Rabbit
- Conjugate
- Unconjugated
- Isotype
- IgG
- Vial size
- 100 µl
- Concentration
- 0.05 mg/ml
- Storage
- Store at +4°C for short term storage. Long time storage is recommended at -20°C.
- Handling
- The antibody solution should be gently mixed before use.
Submitted references Author Correction: The expression pattern of pyruvate dehydrogenase kinases predicts prognosis and correlates with immune exhaustion in clear cell renal cell carcinoma
Heterogeneous Expression and Subcellular Localization of Pyruvate Dehydrogenase Complex in Prostate Cancer
Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells
Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas
Nunes‑Xavier C, Emaldi M, Mingo J, Øyjord T, Mælandsmo G, Fodstad Ø, Errarte P, Larrinaga G, Llarena R, López J, Pulido R
Scientific Reports 2023;13(1)
Scientific Reports 2023;13(1)
Heterogeneous Expression and Subcellular Localization of Pyruvate Dehydrogenase Complex in Prostate Cancer
Nunes-Xavier C, Mingo J, Emaldi M, Flem-Karlsen K, Mælandsmo G, Fodstad Ø, Llarena R, López J, Pulido R
Frontiers in Oncology 2022;12
Frontiers in Oncology 2022;12
Loss of PDPK1 abrogates resistance to gemcitabine in label-retaining pancreatic cancer cells
Li D, Mullinax J, Aiken T, Xin H, Wiegand G, Anderson A, Thorgeirsson S, Avital I, Rudloff U
BMC Cancer 2018;18(1)
BMC Cancer 2018;18(1)
Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas
Fack F, Espedal H, Keunen O, Golebiewska A, Obad N, Harter P, Mittelbronn M, Bähr O, Weyerbrock A, Stuhr L, Miletic H, Sakariassen P, Stieber D, Rygh C, Lund-Johansen M, Zheng L, Gottlieb E, Niclou S, Bjerkvig R
Acta Neuropathologica 2014;129(1):115-131
Acta Neuropathologica 2014;129(1):115-131
No comments: Submit comment
No validations: Submit validation data